Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

581. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis

Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Norrby (...) of patients with sepsis. Searching MEDLINE database and relevant published Cochrane reviews were searched. Search terms and dates were not reported. Study selection Controlled studies of IgM-enriched IVIG treatment in patients with sepsis were eligible for inclusion. Included studies were of IgM-enriched IVIG; dosages ranging from 200mg/100g to 500mg/100g. Control conditions in the included studies were no intervention, 10% dextran or 5% albumin. Study designs included for review were prospective

2006 DARE.

582. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Franca L R, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The addition of drotrecogin alpha (activated) (DAA) to best standard care (BSC) for the treatment of severe sepsis with multiple organ failure (MOF) was examined. DAA was administrated as a continuous intravenous infusion at a rate of 24 microg/kg per hour for 96 hours

2006 NHS Economic Evaluation Database.

583. Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death Full Text available with Trip Pro

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents , Eric B Milbrandt and Lakshmipathi Chelluri Critical Care 2006 10 :316 © BioMed Central Ltd 2006 Published: 03 November 2006 Citation Abraham E, Laterre PF, Garg R, Levy H, Talwar D (...) , Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332–1341 [ ]. Background In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had

2006 Critical Care - EBM Journal Club

584. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Full Text available with Trip Pro

Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. OBJECTIVE: To quantify the accuracy of serum procalcitonin as a diagnostic test for sepsis, severe sepsis, or septic shock in adults in intensive care units or after surgery or trauma, alone and compared with C-reactive protein. To draw and compare the summary receiver operating characteristics curves for procalcitonin and C-reactive protein from (...) the literature. DATA SOURCE: MEDLINE (keywords: procalcitonin, intensive care, sepsis, postoperative sepsis, trauma); screening of the literature. STUDY SELECTION: Meta-analysis of all 49 published studies in medical, surgical, or polyvalent intensive care units or postoperative wards. Children, medical patients, and immunocompromised patients were excluded. DATA EXTRACTION: Thirty-three studies fulfilled inclusion criteria (3,943 patients, 1,828 males, 922 females; mean age: 56.1 yrs; 1,825 patients

2006 EvidenceUpdates

585. Mitochondrial DNA and survival after sepsis: a prospective study. (Abstract)

Mitochondrial DNA and survival after sepsis: a prospective study. Human genome evolution has been shaped by infectious disease. Although most genetic studies have focused on the immune system, recovery after sepsis is directly related to physiological reserve that is critically dependent on mitochondrial function. We investigated whether haplogroup H, the most common type of mitochondrial DNA (mtDNA) in Europe, contributes to the subtle genetic variation in survival after sepsis.In (...) to the intensive care unit, the frequency of mtDNA haplogroup H in study patients did not differ between study patients admitted with severe sepsis and 542 age-matched controls from the northeast of England. MtDNA haplogroup H was a strong independent predictor of outcome during severe sepsis, conferring a 2.12-fold (95% CI 1.02-4.43) increased chance of survival at 180 days compared with individuals without the haplogroup H.Although haplogroup H is the most recent addition to the group of European mtDNA

2005 Lancet

586. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. (Abstract)

Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. Staphylococcus aureus has increasingly been recognized as a cause of severe invasive illness. We describe three children who died at our institution after rapidly progressive clinical deterioration from this infection, with necrotizing pneumonia and multiple-organ-system involvement. The identification of bilateral adrenal hemorrhage at autopsy was characteristic of the Waterhouse-Friderichsen syndrome

2005 NEJM

587. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden

Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden Hjelmgren J, Persson U, Tennvall G (...) Cost-utility analysis and cost-effectiveness analysis. Study population The study population comprised patients with severe sepsis. Setting The study setting was secondary care. The economic study was carried out in Sweden. Dates to which data relate The effectiveness data were derived from a study published in 2001. The price year was 2002. Source of effectiveness data The effectiveness data were derived from the PROWESS trial (Bernard et al. 2001, see 'Other Publications of Related Interest

2005 NHS Economic Evaluation Database.

588. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock

Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

589. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic (...) review and economic evaluation Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson B H CRD summary This review concluded that drotrecogin alfa (activated) is likely to be clinically effective and cost-effective for the treatment of patients with severe sepsis within the UK National Health Service. The review was well conducted and the conclusions are likely to be reliable, although evidence of the treatment's effectiveness came primarily from one large clinical trial

2005 DARE.

590. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Full Text available with Trip Pro

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis Macias W L, Nelson D R, Williams M, Garg R, Janes J, Sashegyi A CRD summary This review assessed the evidence for a relationship between treatment efficacy (...) and disease severity in patients with severe sepsis. The authors concluded that there is no evidence to support a relationship between the severity of disease and the effect of treatment on mortality. Poor reporting and a limited search mean it is not possible to determine the reliability of the conclusions. Authors' objectives To determine whether a relationship exists between the mortality risk of a patient population and the benefit of interventions for severe sepsis. Searching PubMed was searched

2005 DARE.

591. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults (...) )) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technology Assessment 2005; 9(11): 1-140 Authors' objectives The aim of this study was to assess the clinical and cost-effectiveness of drotrecogin alfa (activated) for the treatment of adults with severe sepsis in a UK context. Authors' conclusions Drotrecogin alfa (activated) plus best supportive care appears clinically and cost-effective compared with best supportive care alone, in a UK cohort of severe sepsis

2005 Health Technology Assessment (HTA) Database.

592. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Full Text available with Trip Pro

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus D C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatment strategies for severe sepsis in patients with multiple organ failure were compared, drotrecogin alfa (activated) and placebo (best usual care). Drotrecogin alfa (activated) was supplied in 5-mg vials and was administered as a 96-hour intravenous infusion of 24 microg/kg per hour. Type

2005 NHS Economic Evaluation Database.

593. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. Full Text available with Trip Pro

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death.We randomly assigned adult patients with severe sepsis and a low risk of death (defined by an Acute Physiology and Chronic Health (...) with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.Copyright 2005 Massachusetts Medical Society.

2005 NEJM Controlled trial quality: predicted high

594. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. Full Text available with Trip Pro

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity.To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial.We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare

2005 JAMA Controlled trial quality: uncertain

595. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.

Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

596. Systemic Inflammatory Response and Progression to Severe Sepsis in Critically Ill Infected Patients.

Systemic Inflammatory Response and Progression to Severe Sepsis in Critically Ill Infected Patients. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2005 PedsCCM Evidence-Based Journal Club

597. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. (Abstract)

Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Previous experimental studies have suggested that the triggering receptor expressed on myeloid cells-1 (TREM-1) is specifically upregulated in the presence of microbial products.To evaluate the diagnostic value of plasma levels of the soluble form of TREM-1 in patients admitted with clinical suspicion of infection.Prospective, noninterventional study conducted between (...) inflammatory response syndrome, sepsis, severe sepsis, or septic shock.The systemic inflammatory response syndrome was diagnosed in 29 patients (38%), and sepsis, severe sepsis, or septic shock was diagnosed in the remaining 47 (62%). A plasma soluble TREM-1 level higher than 60 ng/mL was more accurate than any other clinical or laboratory finding for indicating infection (sensitivity, 96% [95% CI, 92% to 100%]; specificity, 89% [CI, 82% to 95%]; positive likelihood ratio, 8.6 [CI, 3.8 to 21.5]; negative

2004 Annals of Internal Medicine

598. Drug intervention trials in sepsis: divergent results. (Abstract)

Drug intervention trials in sepsis: divergent results. Important advances have been made in our understanding of severe sepsis. Outcome can be improved by targeted interventions, including early and appropriate antibiotic therapy and goal-directed resuscitation, and might be further improved by selective decontamination of the digestive tract, tight control of glucose, and possibly by giving corticosteroids to selected patients. Drugs that target specific steps in the septic cascade include (...) than those even in the most successful trial with an antisepsis agents, underscoring the importance of basic measures in severe sepsis. WHERE NEXT? Initial management in severe sepsis should include early goal-directed fluid resuscitation, appropriate antibiotic treatment, and surgical-site control. Intensive-care units should be run by specialists, with adequate medical and nursing staffing. Tight regulation of glucose, selective decontamination of the digestive tract, and moderate-dose

2004 Lancet

599. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Full Text available with Trip Pro

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock.Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials register, the Cochrane central register of controlled trials, Medline, Embase, and LILACS.Two pairs of reviewers agreed on eligibility

2004 BMJ

600. Drotrecogin alfa (activated) for severe sepsis (TA84)

Drotrecogin alfa (activated) for severe sepsis (TA84) Drotrecogin alfa (activated) for severe sepsis | Guidance | NICE Drotrecogin alfa (activated) for severe sepsis Technology appraisal guidance [TA84] Published date: 22 September 2004 Guidance November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint (...) of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis. Explore © NICE [year]. All rights reserved. Subject to .

2004 National Institute for Health and Clinical Excellence - Technology Appraisals